Engineered immune cells injected directly into brain tumors: a new hope?
NCT ID NCT02442297
First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 24 times
Summary
This early-phase study tests a new treatment for people with HER2-positive brain tumors that have come back or not responded to standard care. The treatment involves taking a patient's own immune cells (T cells), adding a special antibody (HER2-CAR) to help them recognize and attack tumor cells, and then injecting these modified cells directly into the brain. The main goals are to find the safest dose and to see if this approach can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR, RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.